TY - JOUR
T1 - Targeting noncoding RNAs to treat atherosclerosis
AU - Sopić, Miron
AU - Vladimirov, Sandra
AU - Munjas, Jelena
AU - Mitić, Tijana
AU - Hall, Ignacio Fernando
AU - Jusic, Amela
AU - Ruzic, Dusan
AU - Devaux, Yvan
AU - AtheroNET COST Action CA21153
N1 - Funding information
British Heart Foundation, Grant/Award Numbers: FS/IPBSRF/22/27, RE/18/5/34216,RE/18/5/34216; Horizon 2020 Framework Programme, Grant/Award Numbers:101016072, 101016072; H2020 Marie Skłodowska-Curie Actions, Grant/Award Numbers: 893435, 893435; HORIZON EUROPE Marie Sklodowska-Curie Actions, Grant/Award Numbers: 101064175, 101086397, 101086397; European Cooperation in Science and Technology, Grant/Award Numbers: COST ACTIONCA21153 AtheroNET Network for implemen, COST ACTION CA21153 AtheroNET Networkfor implemen; Fonds National de la Recherche Luxembourg, Grant/Award Numbers: C14/BM/8225223, C17/BM/11613033, COVID-19/2020-1/14719577/miRCOVID, COVID-19/2020-1/14719577/miRCOVID; Ministarstvo Prosvete, Nauke i TehnoloˇskogRazvoja, Grant/Award Numbers:451-03-66/2024-03/ 200161,451-03-66/2024-03/ 200161
© 2024 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
PY - 2024/5/8
Y1 - 2024/5/8
N2 - Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.
AB - Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.
UR - https://pubmed.ncbi.nlm.nih.gov/38720437
U2 - 10.1111/bph.16412
DO - 10.1111/bph.16412
M3 - Review article
C2 - 38720437
SN - 0007-1188
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
ER -